PF-07104091 + palbociclib + fulvestrant

PF-07104091 + palbociclib + fulvestrant is an investigational combination therapy being studied primarily for the treatment of advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. PF-07104091 is a potent, orally bioavailable and selective cyclin-dependent kinase 2 (CDK2) inhibitor developed by Pfizer. It works by selectively inhibiting CDK2, leading to cell cycle arrest and potential antitumor activity[1][3][8]. Palbociclib is a selective CDK4/6 inhibitor approved for HR-positive, HER2-negative advanced or metastatic breast cancer; it interferes with the growth of cancer cells and is marketed under the brand name Ibrance[7]. Fulvestrant is an estrogen receptor antagonist used in hormone therapy for breast cancer. The combination aims to overcome resistance mechanisms that develop after prior CDK4/6 inhibitor therapies. Clinical trials are ongoing to assess safety, tolerability, and efficacy in heavily pretreated patients with HR-positive/HER2-negative breast cancer who have progressed on previous endocrine therapies including CDK4/6 inhibitors[3][5][6].

Other names

palbociclibfulvestrantTagtociclib